GSK’s (GSK) Buy Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of GSK (LON:GSK) in a research note released on Thursday morning,London Stock Exchange reports. Jefferies Financial Group currently has a GBX 2,450 price objective on the stock.

GSK has been the subject of several other reports. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Citigroup boosted their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research note on Monday, February 9th. Deutsche Bank Aktiengesellschaft increased their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research report on Thursday, January 15th. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Finally, Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of GBX 2,016.43.

GSK Stock Performance

GSK opened at GBX 2,144 on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20. The firm has a market cap of £86.00 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 1.24 and a beta of 0.32. GSK has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 2,282. The stock has a fifty day moving average price of GBX 2,063.87 and a 200-day moving average price of GBX 1,847.87.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, equities research analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In other news, insider Luke Miels sold 15,579 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Also, insider Jonathan Symonds acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was bought at an average cost of GBX 1,951 per share, with a total value of £97,550. In the last three months, insiders have bought 11,447 shares of company stock worth $24,273,097. 0.26% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.